SPECT with simulation measures dose absorption in non-Hodgkin lymphoma

06/10/2013 | Medscape (free registration)

Findings presented at the SNMMI Annual Meeting showed that for patients undergoing I-131 radioimmunotherapy for non-Hodgkin lymphoma, tumor-absorbed dose may help determine progression-free survival. Researchers employed SPECT/CT imaging and Monte Carlo radiation transport simulation to evaluate 3-dimensional dosimetric parameters. Predicted tumor dose was highly correlated with delivered tumor dose, researchers said. The method, which is also being assessed for measuring bone marrow irradiation, has potential to facilitate personalized treatments.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD